We request continued support for the Yale Cancer Center and the continued recognition as an NCI designated comprehensive cancer center. The major focus of the Center is in molecular medicine and the application of the new biology into the clinics to bring about progress in the prevention, diagnosis and treatment of cancer. In this application we request support for 14 research programs, five of which are new restructured programs focusing on specific diseases or scientific thrusts that bridge laboratory and clinical research efforts (Cancer Genetics, Genetic Therapy/Medical Oncology and Hematology, Stem Cell Biology and Transplant, Breast Cancer Research Lymphoma Research), and 14 shared resources, six of which are new since the last application (Biostatistics, Medical Informatics, Rapid Case Ascertainment, Genetic Therapy Human Applications, Genetic Counseling and Gene Targeting Service). In addition a new research program on prostate cancer has been established and supported by YCC, and three former research programs and one shared resource have been phases out. Since the last application a strong recruiting effort has led to restaffing of several YCC programs, and changes in leadership and administrative structure of the Center. We request support for the senior leadership, program directors at a level that reflects their actual time commitment to the center and its programs and for sufficient administrative staff to ensure the continued smooth functioning of the YCC and its evolution as a comprehensive cancer center. The YCC has a robust research base of a total of $54 million dollars in peer reviewed funding of which $13.9 million dollars comes from NCI grants exclusive of the CCSG. Since the last submission major changes have also resulted in a more substantial clinical trials program with strong support for data management and Biostatistics and the establishment of a clinical trials network (The Yale Oncology Network or YON), that will allow the YCC members the flexibility to test the impact of their research results on the practical applications for people with cancer in the YCC catchment area including the undeserved populations in the sphere of influence of YON institutions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-25
Application #
2894460
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1977-12-01
Project End
2003-06-30
Budget Start
1999-08-12
Budget End
2000-06-30
Support Year
25
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Yale University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520
Wang, Shi-Yi; Hsu, Sylvia H; Huang, Siwan et al. (2018) Regional Practice Patterns and Racial/Ethnic Differences in Intensity of End-of-Life Care. Health Serv Res 53:4291-4309
Gettinger, S N; Choi, J; Mani, N et al. (2018) A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nat Commun 9:3196
Liu, Huafeng; Li, Xin; Hu, Li et al. (2018) A crucial role of the PD-1H coinhibitory receptor in suppressing experimental asthma. Cell Mol Immunol 15:838-845
Altwerger, Gary; Bonazzoli, Elena; Bellone, Stefania et al. (2018) In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. Mol Cancer Ther 17:1003-1011
Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40
Kim, Tae Kon; Herbst, Roy S; Chen, Lieping (2018) Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol 39:624-631
Goldberg, Sarah B; Patel, Abhijit A (2018) Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy 10:1023-1025

Showing the most recent 10 out of 675 publications